Read More

Sanofi Makes Statement On FTC Challenge To Proposed License Agreement With Maze Therapeutics; Says We Respectfully Disagree With The Action By The FTC Which Also Delays Potential Advancements That Could Impact The Lives Of Patients

Sanofi is disappointed with the Federal Trade Commission's announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics. The agreement, announced on

SNY

Read More

Leap Therapeutics To Present New Data From Part A Of The DeFianCe Study Of DKN-01 Plus Bevacizumab And Chemotherapy In Colorectal Cancer Patients At The 2024 ASCO Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that the Company will be presenting new data in second-line patients

LPTX

Read More

IN8bio Announces Clinical Update Demonstrating Continued Durable Complete Remission In 100% Of Evaluable Patients In Phase 1 Trial Of INB-100 In Leukemia Presented At The 65th American Society Of Hematology Annual Meeting

Durable complete remission (CR) achieved in 100% of treated patients, including high-risk and relapsed acute myeloid leukemia (AML) patients and those who had failed multiple prior lines of therapy, including

INAB